Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
134 hedge funds and large institutions have $651M invested in Array Biopharma Inc in 2013 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 43 increasing their positions, 41 reducing their positions, and 15 closing their positions.
53% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 15
45% more capital invested
Capital invested by funds: $447M → $651M (+$203M)
5% more funds holding
Funds holding: 128 → 134 (+6)
5% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 41
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
93% less call options, than puts
Call options by funds: $79K | Put options by funds: $1.08M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$15.1M |
| 2 |
PA
Pinnacle Associates
New York
|
+$13.8M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$11.4M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
+$8.7M |
| 5 |
State Street
Boston,
Massachusetts
|
+$7.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$8.39M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$8M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$6.53M |
| 4 |
KIA
Kopp Investment Advisors
Bloomington,
Minnesota
|
-$4.63M |
| 5 |
CIP
Chartwell Investment Partners
Berywn,
Pennsylvania
|
-$4.52M |
ARRY Hedge Fund Activity: Q3 2013 in Review
134 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q3 2013, worth a combined $651M — up 45% from $447M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ARRY positions and 15 closed out — a net gain of 8 holders — while 43 added to existing stakes and 41 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $15.1M. The largest seller was BVF Inc, cutting an estimated $8.39M.
- 134 institutional investors held Array Biopharma Inc (ARRY) as of Q3 2013, up from 128 in Q2 2013.
- Funds reported $651M of Array Biopharma Inc stock for Q3 2013, up 45% quarter-over-quarter.
- 23 funds opened new Array Biopharma Inc positions in Q3 2013 and 15 closed out, a net change of +8 holders.
- The largest Array Biopharma Inc buyer in Q3 2013 was T. Rowe Price Associates, an estimated $15.1M added.
- The largest Array Biopharma Inc seller in Q3 2013 was BVF Inc, an estimated $8.39M sold.
Based on aggregated 13F filings for Q3 2013.